167 related articles for article (PubMed ID: 34228231)
1. Interactions of BRCA1-mutated Breast Cancer Cell Lines with Adipose-derived Stromal Cells (ADSCs).
Plangger A; Haslik W; Rath B; Neumayer C; Hamilton G
J Mammary Gland Biol Neoplasia; 2021 Sep; 26(3):235-245. PubMed ID: 34228231
[TBL] [Abstract][Full Text] [Related]
2. The impact of human adipose tissue-derived stem cells on breast cancer cells: implications for cell-assisted lipotransfers in breast reconstruction.
Koellensperger E; Bonnert LC; Zoernig I; Marmé F; Sandmann S; Germann G; Gramley F; Leimer U
Stem Cell Res Ther; 2017 May; 8(1):121. PubMed ID: 28545495
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-Mediated BRCA1 Knockdown Adipose Stem Cells Promote Breast Cancer Progression.
Zhao R; Kaakati R; Liu X; Xu L; Lee AK; Bachelder R; Li CY; Hollenbeck ST
Plast Reconstr Surg; 2019 Mar; 143(3):747-756. PubMed ID: 30817646
[TBL] [Abstract][Full Text] [Related]
4. Effects of metformin on adipose-derived stromal cell (ADSC) - Breast cancer cell lines interaction.
Teufelsbauer M; Rath B; Plangger A; Staud C; Nanobashvili J; Huk I; Neumayer C; Hamilton G; Radtke C
Life Sci; 2020 Nov; 261():118371. PubMed ID: 32882267
[TBL] [Abstract][Full Text] [Related]
5. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.
Martinez-Outschoorn UE; Balliet R; Lin Z; Whitaker-Menezes D; Birbe RC; Bombonati A; Pavlides S; Lamb R; Sneddon S; Howell A; Sotgia F; Lisanti MP
Cell Cycle; 2012 Dec; 11(23):4402-13. PubMed ID: 23172369
[TBL] [Abstract][Full Text] [Related]
7. Conditioned Medium from Adipose-Derived Stem Cells (ADSCs) Promotes Epithelial-to-Mesenchymal-Like Transition (EMT-Like) in Glioma Cells In vitro.
Iser IC; Ceschini SM; Onzi GR; Bertoni AP; Lenz G; Wink MR
Mol Neurobiol; 2016 Dec; 53(10):7184-7199. PubMed ID: 26687184
[TBL] [Abstract][Full Text] [Related]
8. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modulation of BRCA1 and BRCA2 gene expression by equol in breast cancer cell lines.
Bosviel R; Durif J; Déchelotte P; Bignon YJ; Bernard-Gallon D
Br J Nutr; 2012 Oct; 108(7):1187-93. PubMed ID: 22217331
[TBL] [Abstract][Full Text] [Related]
10. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Rauh-Adelmann C; Lau KM; Sabeti N; Long JP; Mok SC; Ho SM
Mol Carcinog; 2000 Aug; 28(4):236-46. PubMed ID: 10972993
[TBL] [Abstract][Full Text] [Related]
12. Effects of metformin on human bone-derived mesenchymal stromal cell-breast cancer cell line interactions.
Teufelsbauer M; Lang C; Plangger A; Rath B; Moser D; Staud C; Radtke C; Neumayer C; Hamilton G
Med Oncol; 2022 Feb; 39(5):54. PubMed ID: 35150338
[TBL] [Abstract][Full Text] [Related]
13. iPSC-Derived Hereditary Breast Cancer Model Reveals the
Portier L; Desterke C; Chaker D; Oudrhiri N; Asgarova A; Dkhissi F; Turhan AG; Bennaceur-Griscelli A; Griscelli F
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513753
[TBL] [Abstract][Full Text] [Related]
14. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
15. The effect of human umbilical cord mesenchymal stem cells conditioned medium combined with tamoxifen drug on BRCA1 and BRCA2 expression in breast cancer mouse models.
Panahandeh AR; Delashoub M; Aval SF
Mol Biol Rep; 2024 Feb; 51(1):241. PubMed ID: 38300337
[TBL] [Abstract][Full Text] [Related]
16.
Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
[No Abstract] [Full Text] [Related]
17. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
Holstege H; van Beers E; Velds A; Liu X; Joosse SA; Klarenbeek S; Schut E; Kerkhoven R; Klijn CN; Wessels LF; Nederlof PM; Jonkers J
BMC Cancer; 2010 Aug; 10():455. PubMed ID: 20735817
[TBL] [Abstract][Full Text] [Related]
18. Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.
Walker LC; Thompson BA; Waddell N; ; Grimmond SM; Spurdle AB
PLoS Genet; 2010 Feb; 6(2):e1000850. PubMed ID: 20174566
[TBL] [Abstract][Full Text] [Related]
19. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF
BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407
[TBL] [Abstract][Full Text] [Related]
20. Retarding breast tumor growth with nanoparticle-facilitated intravenous delivery of BRCA1 and BRCA2 tumor suppressor genes.
Ibnat N; Chowdhury EH
Sci Rep; 2023 Jan; 13(1):536. PubMed ID: 36631481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
